Gland Pharma Ltd - Base Business Faces Volume Decline; New Launches Offer Optimism
GLAND’s base business (Ex-Cenexi) registered an 8% YoY revenue degrowth due to lower volumes; however, EBITDA margins expanded to ~38.7%, improving...
246 Views
Gland Pharma Ltd - Margins Impacted by Cenexi Business; Maintain HOLD
GLAND (Ex-Cenexi) registered a muted revenue growth of 5.1% YoY due to the annual shutdown of planned maintenance, maintaining EBITDA margins of...
242 Views
Gland Pharma Ltd - Margins Impacted by Subsidiary; Maintain HOLD
GLAND (Ex-Cenexi) registered a revenue growth of 14.2% YoY, maintaining EBITDA margins of ~29%, which is in line with preceding quarters on a YoY...
274 Views
Gland Pharma Ltd - Operating Losses in Subsidiary; Maintain HOLD
GLAND (Ex-Cenexi) registered consistent revenue growth of 49.5% YoY, maintaining EBITDA margins of ~34%, which is in line with preceding quarters.
220 Views
Gland Pharma - Performance in Revival Mode; Valuation Attractive
Gland Pharma (GLAND) has seen an encouraging revival in its business performance in 9MFY24 after a weak FY23. The revival in sales in the...
432 Views